TLX250-CDx (89Zr)
Kidney Cancer (Clear Cell RCC) Imaging
Phase IIIActive (ZIRCON)
Key Facts
Indication
Kidney Cancer (Clear Cell RCC) Imaging
Phase
Phase III
Status
Active (ZIRCON)
Company
About Telix Pharmaceuticals
Telix Pharmaceuticals is a leader in the radiopharmaceutical space, focused on delivering precision oncology through targeted radiation. The company has achieved commercial success with its prostate cancer imaging agent Illuccix® and is advancing a deep pipeline of theranostic candidates, including its pivotal Phase III therapy program for prostate cancer (ProstACT). With a global operational footprint, including a major manufacturing facility in Belgium, Telix is positioned to scale its innovative platform across multiple high-need cancer indications.
View full company profile